Abstract
Effectiveness and safety of ixazomib–lenalidomide–dexamethasone in high-cytogenetic-risk relapsed/refractory multiple myeloma — results of the Polish Myeloma Group observational study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have